- Home
- MIST vs UNCY Comparison
MIST vs UNCY Comparison
Compare MIST & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | UNCY |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 100.6M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIST | UNCY |
|---|---|---|
| Price | $0.73 | $3.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $5.57 | ★ $28.40 |
| AVG Volume (30 Days) | 934.7K | ★ 1.0M |
| Earning Date | 11-16-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $125.44 | N/A |
| Revenue Next Year | $462.63 | $10,044.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $3.35 |
| 52 Week High | $3.06 | $8.74 |
Technical Indicators
Market Signals| Indicator | MIST | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 34.90 |
| Support Level | $0.63 | $3.35 |
| Resistance Level | $1.42 | $4.18 |
| Average True Range (ATR) | 0.06 | 0.26 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 58.27 | 19.42 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.